Global GLP Analogs Market

GLP Analogs Comprehensive Study by Drug (Exenatide, Liraglutide, Lixisenatide, Dulaglutide, Semaglutide, Albiglutide), Distribution Channel (Retail Pharmacy, Hospital Pharmacy) Players and Region - Global Market Outlook to 2030

GLP Analogs Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 4.8%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
GLP Analogs Market Scope
Glucagon-like peptide-1 agonists are a category of medicines utilized within the treatment of type 2 diabetes and obesity. The utilization of an inter-professional team of nurses, medical aid providers, pharmacists, also as endocrinologists remains pertinent to worry for patients prescribed this class of medicines. It also helps enhance the assembly of insulin. GLP-1 is produced within the gut. The cells within the bowel are the most source of GLP-1. The pancreas and nervous system also produce GLP-1, but in smaller amounts. GLP-1 helps you are feeling full during and between meals by working with the brain and by slowly emptying the stomach. GLP-1 analogues are currently approved for treatment of T2DM as mono-therapy and as add-on therapy to existing anti-diabetes medication (mono, dual, or triple therapy). They need shown to enhance HbA1c by 0.6 to 1.5% with sustained advantage of >1% over a three-year study period. Diabetes is one in every of the fastest growing global health emergencies of the 21st century. According to IDF Diabetes Atlas the patients suffering from diabetes were 463 million people have diabetes in 2019, and this number is projected to achieve 578 million by 2030, and 700 million by 2045.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
Key Companies ProfiledNovo Nordisk (Denmark), Sanofi (France), Eli Lilly (United States) and AstraZeneca (United Kingdom)
CAGR4.8%


The market is seeing moderate market players, by seeing huge growth in this market the key leading vendors are highly focusing on production technologies, efficiency enhancement, and product life. This market has various growth opportunities that leading players capture via tracking the ongoing process enhancement and huge investment in market growth strategies.

Novo Nordisk (Denmark), Sanofi (France), Eli Lilly (United States) and AstraZeneca (United Kingdom) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global GLP Analogs market by Type and Region with country level break-up.

On the basis of geography, the market of GLP Analogs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2023.

Market Leaders and their expansionary development strategies
In August 2023, Eli Lilly and Company acquired Akcea Therapeutics for USD 9.3 billion. Akcea's razutagliden pegol, a long-acting GLP-1 receptor agonist, was a key driver for this acquisition, expanding Lilly's diabetes portfolio.
In April 2021, Boehringer Ingelheim launched Jardiance® (empagliflozin) in a new once-weekly dosage option, providing a convenient treatment option for type 2 diabetes patients.


Influencing Trend:
Initiatives by Several Government over Diabetes Care Drugs

Market Growth Drivers:
Rising Number of Diabetic Patient, Uptake of Novel Drugs Drive Sales and Complexity of Alternative Diabetes Management Therapies

Challenges:
Growing Competition and Consolidation of Retail Pharmacy Chains

Restraints:
Low Patient Awareness and Cost Sensitivity

Opportunities:
Growing Adoption of Diabetes Vaccines & Inhalable Insulin and Increasing Diabetes Care Centers

Key Target Audience
Pharmaceutical Companies, Research and Development (R&D) Companies, Research Organization, Federal Agencies, Potential Technology Investors, Regulatory & Government Bodies and Others

Report Objectives / Segmentation Covered

By Drug
  • Exenatide
  • Liraglutide
  • Lixisenatide
  • Dulaglutide
  • Semaglutide
  • Albiglutide

By Distribution Channel
  • Retail Pharmacy
  • Hospital Pharmacy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Number of Diabetic Patient
      • 3.2.2. Uptake of Novel Drugs Drive Sales
      • 3.2.3. Complexity of Alternative Diabetes Management Therapies
    • 3.3. Market Challenges
      • 3.3.1. Growing Competition and Consolidation of Retail Pharmacy Chains
    • 3.4. Market Trends
      • 3.4.1. Initiatives by Several Government over Diabetes Care Drugs
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global GLP Analogs, by Drug, Distribution Channel and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global GLP Analogs (Value)
      • 5.2.1. Global GLP Analogs by: Drug (Value)
        • 5.2.1.1. Exenatide
        • 5.2.1.2. Liraglutide
        • 5.2.1.3. Lixisenatide
        • 5.2.1.4. Dulaglutide
        • 5.2.1.5. Semaglutide
        • 5.2.1.6. Albiglutide
      • 5.2.2. Global GLP Analogs by: Distribution Channel (Value)
        • 5.2.2.1. Retail Pharmacy
        • 5.2.2.2. Hospital Pharmacy
      • 5.2.3. Global GLP Analogs Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. GLP Analogs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novo Nordisk (Denmark)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sanofi (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Eli Lilly (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. AstraZeneca (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
  • 7. Global GLP Analogs Sale, by Drug, Distribution Channel and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global GLP Analogs (Value)
      • 7.2.1. Global GLP Analogs by: Drug (Value)
        • 7.2.1.1. Exenatide
        • 7.2.1.2. Liraglutide
        • 7.2.1.3. Lixisenatide
        • 7.2.1.4. Dulaglutide
        • 7.2.1.5. Semaglutide
        • 7.2.1.6. Albiglutide
      • 7.2.2. Global GLP Analogs by: Distribution Channel (Value)
        • 7.2.2.1. Retail Pharmacy
        • 7.2.2.2. Hospital Pharmacy
      • 7.2.3. Global GLP Analogs Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. GLP Analogs: by Drug(USD Million)
  • Table 2. GLP Analogs Exenatide , by Region USD Million (2018-2023)
  • Table 3. GLP Analogs Liraglutide , by Region USD Million (2018-2023)
  • Table 4. GLP Analogs Lixisenatide , by Region USD Million (2018-2023)
  • Table 5. GLP Analogs Dulaglutide , by Region USD Million (2018-2023)
  • Table 6. GLP Analogs Semaglutide , by Region USD Million (2018-2023)
  • Table 7. GLP Analogs Albiglutide , by Region USD Million (2018-2023)
  • Table 8. GLP Analogs: by Distribution Channel(USD Million)
  • Table 9. GLP Analogs Retail Pharmacy , by Region USD Million (2018-2023)
  • Table 10. GLP Analogs Hospital Pharmacy , by Region USD Million (2018-2023)
  • Table 11. South America GLP Analogs, by Country USD Million (2018-2023)
  • Table 12. South America GLP Analogs, by Drug USD Million (2018-2023)
  • Table 13. South America GLP Analogs, by Distribution Channel USD Million (2018-2023)
  • Table 14. Brazil GLP Analogs, by Drug USD Million (2018-2023)
  • Table 15. Brazil GLP Analogs, by Distribution Channel USD Million (2018-2023)
  • Table 16. Argentina GLP Analogs, by Drug USD Million (2018-2023)
  • Table 17. Argentina GLP Analogs, by Distribution Channel USD Million (2018-2023)
  • Table 18. Rest of South America GLP Analogs, by Drug USD Million (2018-2023)
  • Table 19. Rest of South America GLP Analogs, by Distribution Channel USD Million (2018-2023)
  • Table 20. Asia Pacific GLP Analogs, by Country USD Million (2018-2023)
  • Table 21. Asia Pacific GLP Analogs, by Drug USD Million (2018-2023)
  • Table 22. Asia Pacific GLP Analogs, by Distribution Channel USD Million (2018-2023)
  • Table 23. China GLP Analogs, by Drug USD Million (2018-2023)
  • Table 24. China GLP Analogs, by Distribution Channel USD Million (2018-2023)
  • Table 25. Japan GLP Analogs, by Drug USD Million (2018-2023)
  • Table 26. Japan GLP Analogs, by Distribution Channel USD Million (2018-2023)
  • Table 27. India GLP Analogs, by Drug USD Million (2018-2023)
  • Table 28. India GLP Analogs, by Distribution Channel USD Million (2018-2023)
  • Table 29. South Korea GLP Analogs, by Drug USD Million (2018-2023)
  • Table 30. South Korea GLP Analogs, by Distribution Channel USD Million (2018-2023)
  • Table 31. Taiwan GLP Analogs, by Drug USD Million (2018-2023)
  • Table 32. Taiwan GLP Analogs, by Distribution Channel USD Million (2018-2023)
  • Table 33. Australia GLP Analogs, by Drug USD Million (2018-2023)
  • Table 34. Australia GLP Analogs, by Distribution Channel USD Million (2018-2023)
  • Table 35. Rest of Asia-Pacific GLP Analogs, by Drug USD Million (2018-2023)
  • Table 36. Rest of Asia-Pacific GLP Analogs, by Distribution Channel USD Million (2018-2023)
  • Table 37. Europe GLP Analogs, by Country USD Million (2018-2023)
  • Table 38. Europe GLP Analogs, by Drug USD Million (2018-2023)
  • Table 39. Europe GLP Analogs, by Distribution Channel USD Million (2018-2023)
  • Table 40. Germany GLP Analogs, by Drug USD Million (2018-2023)
  • Table 41. Germany GLP Analogs, by Distribution Channel USD Million (2018-2023)
  • Table 42. France GLP Analogs, by Drug USD Million (2018-2023)
  • Table 43. France GLP Analogs, by Distribution Channel USD Million (2018-2023)
  • Table 44. Italy GLP Analogs, by Drug USD Million (2018-2023)
  • Table 45. Italy GLP Analogs, by Distribution Channel USD Million (2018-2023)
  • Table 46. United Kingdom GLP Analogs, by Drug USD Million (2018-2023)
  • Table 47. United Kingdom GLP Analogs, by Distribution Channel USD Million (2018-2023)
  • Table 48. Netherlands GLP Analogs, by Drug USD Million (2018-2023)
  • Table 49. Netherlands GLP Analogs, by Distribution Channel USD Million (2018-2023)
  • Table 50. Rest of Europe GLP Analogs, by Drug USD Million (2018-2023)
  • Table 51. Rest of Europe GLP Analogs, by Distribution Channel USD Million (2018-2023)
  • Table 52. MEA GLP Analogs, by Country USD Million (2018-2023)
  • Table 53. MEA GLP Analogs, by Drug USD Million (2018-2023)
  • Table 54. MEA GLP Analogs, by Distribution Channel USD Million (2018-2023)
  • Table 55. Middle East GLP Analogs, by Drug USD Million (2018-2023)
  • Table 56. Middle East GLP Analogs, by Distribution Channel USD Million (2018-2023)
  • Table 57. Africa GLP Analogs, by Drug USD Million (2018-2023)
  • Table 58. Africa GLP Analogs, by Distribution Channel USD Million (2018-2023)
  • Table 59. North America GLP Analogs, by Country USD Million (2018-2023)
  • Table 60. North America GLP Analogs, by Drug USD Million (2018-2023)
  • Table 61. North America GLP Analogs, by Distribution Channel USD Million (2018-2023)
  • Table 62. United States GLP Analogs, by Drug USD Million (2018-2023)
  • Table 63. United States GLP Analogs, by Distribution Channel USD Million (2018-2023)
  • Table 64. Canada GLP Analogs, by Drug USD Million (2018-2023)
  • Table 65. Canada GLP Analogs, by Distribution Channel USD Million (2018-2023)
  • Table 66. Mexico GLP Analogs, by Drug USD Million (2018-2023)
  • Table 67. Mexico GLP Analogs, by Distribution Channel USD Million (2018-2023)
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. GLP Analogs: by Drug(USD Million)
  • Table 73. GLP Analogs Exenatide , by Region USD Million (2025-2030)
  • Table 74. GLP Analogs Liraglutide , by Region USD Million (2025-2030)
  • Table 75. GLP Analogs Lixisenatide , by Region USD Million (2025-2030)
  • Table 76. GLP Analogs Dulaglutide , by Region USD Million (2025-2030)
  • Table 77. GLP Analogs Semaglutide , by Region USD Million (2025-2030)
  • Table 78. GLP Analogs Albiglutide , by Region USD Million (2025-2030)
  • Table 79. GLP Analogs: by Distribution Channel(USD Million)
  • Table 80. GLP Analogs Retail Pharmacy , by Region USD Million (2025-2030)
  • Table 81. GLP Analogs Hospital Pharmacy , by Region USD Million (2025-2030)
  • Table 82. South America GLP Analogs, by Country USD Million (2025-2030)
  • Table 83. South America GLP Analogs, by Drug USD Million (2025-2030)
  • Table 84. South America GLP Analogs, by Distribution Channel USD Million (2025-2030)
  • Table 85. Brazil GLP Analogs, by Drug USD Million (2025-2030)
  • Table 86. Brazil GLP Analogs, by Distribution Channel USD Million (2025-2030)
  • Table 87. Argentina GLP Analogs, by Drug USD Million (2025-2030)
  • Table 88. Argentina GLP Analogs, by Distribution Channel USD Million (2025-2030)
  • Table 89. Rest of South America GLP Analogs, by Drug USD Million (2025-2030)
  • Table 90. Rest of South America GLP Analogs, by Distribution Channel USD Million (2025-2030)
  • Table 91. Asia Pacific GLP Analogs, by Country USD Million (2025-2030)
  • Table 92. Asia Pacific GLP Analogs, by Drug USD Million (2025-2030)
  • Table 93. Asia Pacific GLP Analogs, by Distribution Channel USD Million (2025-2030)
  • Table 94. China GLP Analogs, by Drug USD Million (2025-2030)
  • Table 95. China GLP Analogs, by Distribution Channel USD Million (2025-2030)
  • Table 96. Japan GLP Analogs, by Drug USD Million (2025-2030)
  • Table 97. Japan GLP Analogs, by Distribution Channel USD Million (2025-2030)
  • Table 98. India GLP Analogs, by Drug USD Million (2025-2030)
  • Table 99. India GLP Analogs, by Distribution Channel USD Million (2025-2030)
  • Table 100. South Korea GLP Analogs, by Drug USD Million (2025-2030)
  • Table 101. South Korea GLP Analogs, by Distribution Channel USD Million (2025-2030)
  • Table 102. Taiwan GLP Analogs, by Drug USD Million (2025-2030)
  • Table 103. Taiwan GLP Analogs, by Distribution Channel USD Million (2025-2030)
  • Table 104. Australia GLP Analogs, by Drug USD Million (2025-2030)
  • Table 105. Australia GLP Analogs, by Distribution Channel USD Million (2025-2030)
  • Table 106. Rest of Asia-Pacific GLP Analogs, by Drug USD Million (2025-2030)
  • Table 107. Rest of Asia-Pacific GLP Analogs, by Distribution Channel USD Million (2025-2030)
  • Table 108. Europe GLP Analogs, by Country USD Million (2025-2030)
  • Table 109. Europe GLP Analogs, by Drug USD Million (2025-2030)
  • Table 110. Europe GLP Analogs, by Distribution Channel USD Million (2025-2030)
  • Table 111. Germany GLP Analogs, by Drug USD Million (2025-2030)
  • Table 112. Germany GLP Analogs, by Distribution Channel USD Million (2025-2030)
  • Table 113. France GLP Analogs, by Drug USD Million (2025-2030)
  • Table 114. France GLP Analogs, by Distribution Channel USD Million (2025-2030)
  • Table 115. Italy GLP Analogs, by Drug USD Million (2025-2030)
  • Table 116. Italy GLP Analogs, by Distribution Channel USD Million (2025-2030)
  • Table 117. United Kingdom GLP Analogs, by Drug USD Million (2025-2030)
  • Table 118. United Kingdom GLP Analogs, by Distribution Channel USD Million (2025-2030)
  • Table 119. Netherlands GLP Analogs, by Drug USD Million (2025-2030)
  • Table 120. Netherlands GLP Analogs, by Distribution Channel USD Million (2025-2030)
  • Table 121. Rest of Europe GLP Analogs, by Drug USD Million (2025-2030)
  • Table 122. Rest of Europe GLP Analogs, by Distribution Channel USD Million (2025-2030)
  • Table 123. MEA GLP Analogs, by Country USD Million (2025-2030)
  • Table 124. MEA GLP Analogs, by Drug USD Million (2025-2030)
  • Table 125. MEA GLP Analogs, by Distribution Channel USD Million (2025-2030)
  • Table 126. Middle East GLP Analogs, by Drug USD Million (2025-2030)
  • Table 127. Middle East GLP Analogs, by Distribution Channel USD Million (2025-2030)
  • Table 128. Africa GLP Analogs, by Drug USD Million (2025-2030)
  • Table 129. Africa GLP Analogs, by Distribution Channel USD Million (2025-2030)
  • Table 130. North America GLP Analogs, by Country USD Million (2025-2030)
  • Table 131. North America GLP Analogs, by Drug USD Million (2025-2030)
  • Table 132. North America GLP Analogs, by Distribution Channel USD Million (2025-2030)
  • Table 133. United States GLP Analogs, by Drug USD Million (2025-2030)
  • Table 134. United States GLP Analogs, by Distribution Channel USD Million (2025-2030)
  • Table 135. Canada GLP Analogs, by Drug USD Million (2025-2030)
  • Table 136. Canada GLP Analogs, by Distribution Channel USD Million (2025-2030)
  • Table 137. Mexico GLP Analogs, by Drug USD Million (2025-2030)
  • Table 138. Mexico GLP Analogs, by Distribution Channel USD Million (2025-2030)
  • Table 139. Research Programs/Design for This Report
  • Table 140. Key Data Information from Secondary Sources
  • Table 141. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global GLP Analogs: by Drug USD Million (2018-2023)
  • Figure 5. Global GLP Analogs: by Distribution Channel USD Million (2018-2023)
  • Figure 6. South America GLP Analogs Share (%), by Country
  • Figure 7. Asia Pacific GLP Analogs Share (%), by Country
  • Figure 8. Europe GLP Analogs Share (%), by Country
  • Figure 9. MEA GLP Analogs Share (%), by Country
  • Figure 10. North America GLP Analogs Share (%), by Country
  • Figure 11. Global GLP Analogs share by Players 2023 (%)
  • Figure 12. BCG Matrix for key Companies
  • Figure 13. Novo Nordisk (Denmark) Revenue, Net Income and Gross profit
  • Figure 14. Novo Nordisk (Denmark) Revenue: by Geography 2023
  • Figure 15. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 16. Sanofi (France) Revenue: by Geography 2023
  • Figure 17. Eli Lilly (United States) Revenue, Net Income and Gross profit
  • Figure 18. Eli Lilly (United States) Revenue: by Geography 2023
  • Figure 19. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. AstraZeneca (United Kingdom) Revenue: by Geography 2023
  • Figure 21. Global GLP Analogs: by Drug USD Million (2025-2030)
  • Figure 22. Global GLP Analogs: by Distribution Channel USD Million (2025-2030)
  • Figure 23. South America GLP Analogs Share (%), by Country
  • Figure 24. Asia Pacific GLP Analogs Share (%), by Country
  • Figure 25. Europe GLP Analogs Share (%), by Country
  • Figure 26. MEA GLP Analogs Share (%), by Country
  • Figure 27. North America GLP Analogs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Novo Nordisk (Denmark)
  • Sanofi (France)
  • Eli Lilly (United States)
  • AstraZeneca (United Kingdom)
Select User Access Type

Key Highlights of Report


Feb 2024 215 Pages 91 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global GLP Analogs Market Quantitative research analysis
Global GLP Analogs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in GLP Analogs Market are by end use application [].
The GLP Analogs Market is gaining popularity and expected to see strong valuation by 2030.
  • Rising Number of Diabetic Patient
  • Uptake of Novel Drugs Drive Sales
  • Complexity of Alternative Diabetes Management Therapies

Know More About Global GLP Analogs Market Report?

Have a Query? Click Here

Other Related Reports

Crohn’s Disease Treatment Comprehensive Study by Type (Drug (Anti-inflammatory drugs, Oral 5-aminosalicylates, Biologics, Antibiotics, and Other), Nutrition Therapy, Surgery), Route of Administration...
$ 3450
Parkinson’s Disease Therapeutics Comprehensive Study by Distribution Channel (Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies), Route of Administration (Oral, Parental (Rectal, Intranasa...
$ 3650
Stye Drugs Comprehensive Study by Type (Hordeolum, Chalazion), Rout of Administration (Oral, Topical, Injectible), Prescription mode (Over-the-counter, Prescription-based), Distribution Channel (Hos...
$ 3750
Tinnitus Drug Pipeline Comprehensive Study by Type (Anti-Depressants, Anti- Anxiety, Anti-Histamines, Anti-Convulsant), Distribution Channel (Retail Pharmacies, Drug Stores, E-Commerce) Players and R...
$ 3500
Rivanol Comprehensive Study by Type (Powder, Solution), Application (Individual, Commercial), Distribution Channel (Online, Offline) Players and Region - Global Market Outlook to 2026
$ 3500
COPD Medicine Comprehensive Study by Type (Emphysema, Chronic bronchitis), Route of Administration (Inhalation, Enteral, Parenteral), Distribution Channel (Hospital pharmacy, Retail pharmacy, Online ...
$ 3750